Skip to main content
OpenTrials
Completed

NCT Number: NCT05341128

A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China

The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them.

There are no participants in this trial, the study only involves reviewing participants medical past and current records and collecting information.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Central Precocious Puberty Endocrine System Diseases Gonadal Disorders Puberty, Precocious

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Loading trial locations.

About this study

This is an observational, non-interventional, retrospective study to evaluate the participants characteristics, current treatment patterns and resource usage in Chinese pediatric participants diagnosed with CPP.

This study will enroll approximately 1000 participants.

The data available in an existing data source the Chinese CPP Big Data Platform database will be analyzed. All the participants will be assigned to a single observational cohort:

  • Pediatric Participants With CPP

This multi-center trial will be conducted in China. The overall duration of the study will be approximately 3 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants diagnosed with CPP and treated with GnRHa from the centers participating in this study within the Chinese CPP Big Data Platform database since 2015 to 2024.

CPP diagnosis is based on the clinical assessment and description by CPP specialized doctors.

Exclusion criteria

  • Not received GnRHa as the treatment for CPP.
  • No available data for analysis.

Treatment and study plan

Primary outcomes

  1. Percentage of Participants With CPP Treatment

    Time frame: Up to approximately 10 years

Secondary outcomes

  1. Percentage of Participants With CPP Treatment at Baseline

    Time frame: At Baseline

  2. Percentage of Participants With Luteinizing hormone (LH) Suppression

    Time frame: Baseline up to approximately 10 years

  3. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 10 years

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

Patient Characteristics, Treatment Patterns, and Resource Usage in Children Diagnosed With Central Precocious Puberty (CPP) in China

Acronym: PACTURE

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Apr 22, 2022
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.